摘要激活的特异性T细胞具有直接识别并清除肿瘤细胞的能力，在抗肿瘤免疫应答中发挥关键作用。近年来，肿瘤免疫治疗领域，特别是基于T细胞的治疗策略取得了快速进展，多种药物获得临床批准，大量基础研究与临床试验正在进行。在这些策略中，过继性T细胞疗法成为主要焦点，包括嵌合抗原受体T细胞(chimeric antigen receptor T-cell，CAR-T)、T细胞受体工程化T细胞(T-cell receptor engineering T cell，TCR-T)、肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes，TILs)、细胞毒性T淋巴细胞(cytotoxic T lymphocytes，CTLs)疗法等。本文概括了4类过继性T细胞疗法的全球研究和开发进展，同时剖析了各自的优点和局限性，以期为肿瘤免疫治疗药物研发和临床肿瘤治疗应用提供参考。

abstractsActivated specific T cells possess the capability to directly recognize and eradicate tumor cells, a process pivotal in the anti-tumor immune response. In recent years, the field of tumor immunotherapy, particularly T cell-based strategies, has seen rapid advancements, resulting in several drugs receiving clinical approval and the initiation of numerous basic research endeavors and clinical trials. Among these strategies, adoptive T cell transfer therapy emerges as a principal focus, encompassing approaches such as chimeric antigen receptor T-cell (CAR-T), T-cell receptor-engineered T cell (TCR-T), tumor-infiltrating lymphocytes (TILs), and cytotoxic T lymphocytes (CTLs) therapies. This review endeavors to encapsulate the global research and development strides made in four categories of adoptive T cell therapies, while also dissecting their individual merits and limitations. The objective is to furnish insights that may bolster the development of tumor immunotherapy pharmacopeia and their efficacious clinical application in cancer treatment.